---
document_datetime: 2026-01-27 14:39:58
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/beovu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: beovu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2889127
conversion_datetime: 2026-01-29 11:50:44.870145
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Beovu

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA / | A.ADMINISTRATIVECHANGES-A.7 | 27/01/2026                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323553                     | Deletionofmanufacturingsitesforanactive substance, intermediate or finished product, packagingsite,manufacturerresponsiblefor batch release, site where batch control takes place,orsupplierofastartingmaterial, reagentorexcipient(when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                            |            |     | PL                     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| Variation type IB / EMA/VR/0000270099 | B.I.b.1 Change in the specification parameters and/or limits of an active substance,startingmaterial/intermediate/ reagentused in themanufacturingprocess of the active substance-B.1.b.1.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                      | 04/06/2025 | N/A |                        |
| Variation type IB / EMA/VR/0000263496 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.z Change(s)in the SmPC, labelling or package leaflet of human medicinalproductsinordertoadapttoa recommendation of a competent authority , e.g. a Core SmPC, following the assessment of anUrgentSafetyRestrictionetc. Implementationofwordingagreedbythe competent authority thatrequire additional minor assessment,e.g.translations are not yet agreed upon.- Accepted C.I.z-To update section 6.1 of the SmPC, section3of theLabellingandsection6of the PL to include pH adjusters on the list of excipientsinlinewithVolume2C Guidelines | 19/05/2025 |     | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | \"Excipients in the labelling and package leaflet of medicinal productsforhuman use\".                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000256246 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in themanufacturingprocessof the active substanceorchangeinthemanufacturer (including where relevant quality control testing sites)of the activesubstance,where noPh.Eur.Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the activesubstance-replacementor additionof asitewherebatchcontrol/testingtakes place - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z | 08/04/2025 | N/A |